Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical Services Holdings Limited reports developments as a China-based oncology healthcare provider focused on cancer diagnosis, treatment, research, education and prevention. Its updates center on self-owned cancer hospitals and clinics, partnered hospitals, and oncology service lines that include radiotherapy, diagnostic imaging, hospital operations and premium cancer care.
Recurring news covers financial results for the hospital and network businesses, annual reports on Form 20-F, shareholder meetings, and governance actions. Company and subsidiary announcements also address Concord Healthcare Group, its Hong Kong-listed H shares, proton therapy operations at Guangzhou Concord Cancer Hospital, medical-device approvals tied to proton equipment, treatment milestones, and oncology technology such as a proton therapy large language model.
Concord Medical (NYSE: CCM) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 29, 2026.
An electronic copy is available on Concord Medical's investor relations website and on the SEC website; shareholders can request a free hard copy via the investor site.
Concord Medical (NYSE: CCM) will hold its 2025 annual general meeting of shareholders on December 29, 2025 at 10:00 a.m. Beijing Time at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing.
The shareholder record date is December 19, 2025. No proposals will be submitted for shareholder approval; the meeting is convened for entitled shareholders to discuss company affairs with management.
The company's Form 20-F containing audited financial statements for the year ended December 31, 2024 is available on the company's investor relations website and the SEC website.
Concord Medical (NYSE:CCM), a Chinese cancer treatment healthcare provider, reported its H1 2025 financial results showing mixed performance. Total net revenues decreased 8.3% to RMB200.6 million (US$28.0 million), with hospital business revenues increasing 11.1% to RMB153.0 million and network business revenues declining 41.3% to RMB47.6 million.
The company significantly reduced its losses, with net loss attributable to shareholders improving to RMB27.1 million (US$3.8 million) from RMB172.3 million year-over-year. Gross loss margin improved to 2.1% from 19.0%. The improvement was largely driven by the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital and enhanced operational efficiency.
As of June 30, 2025, CCM maintained bank loans and borrowings of RMB3.6 billion (US$508.4 million), while capital expenditures decreased to RMB100.6 million from RMB168.4 million year-over-year.
Concord Healthcare Group (NYSE: CCM) has achieved a significant medical milestone by completing China's first proton therapy treatment for choroidal malignant melanoma at its Guangzhou Concord Cancer Center. The innovative treatment, performed on July 11, 2025, offers an alternative to traditional eye removal surgery.
The center employs advanced pencil beam scanning proton therapy with real-time image guidance, enabling precise high-dose radiation delivery while protecting surrounding tissues. This breakthrough provides Chinese patients with a vision-preserving treatment option, establishing Guangzhou Concord Cancer Center as the first medical institution in China to offer this specialized treatment.
Concord Healthcare Group (NYSE: CCM), a subsidiary of Concord Medical Services Holdings, has officially launched China's first large language model (LLM) specialized in proton therapy. The model has been successfully deployed at Guangzhou Concord Cancer Hospital, where it has already demonstrated success in multiple patient treatment cases.
The LLM integrates nearly 10,000 high-quality radiotherapy cases, incorporating multimodal medical data, Proton China data, and professional journal literature. The technology has shown promising results with precise treatment capabilities, significant efficacy, and reduced side effects. This development builds on Concord Healthcare's extensive experience in tumor diagnosis and treatment technology.
Concord Medical Services Holdings (NYSE: CCM), a Chinese healthcare provider specializing in cancer treatment, research, education and prevention, has announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission.
The electronic copy of the Annual Report is accessible on Concord Medical's investor relations website and the SEC's website. Shareholders can request free hard copies of the audited financial statements through the company's investor relations portal.
Concord Medical Services Holdings (NYSE: CCM), a Chinese healthcare provider specializing in cancer treatment, research, education, and prevention, held its 2024 annual general meeting on December 27, 2024. During the meeting, shareholders approved a special resolution to adopt the Fifth Amended and Restated Memorandum and Articles of Association, replacing the previous Fourth Memorandum and Articles of Association.
Concord Medical Services Holdings (NYSE: CCM) announced that China's National Medical Products Administration has approved the Registration Certificate for Medical Device for their proton therapy equipment on December 6, 2024. The company's Guangzhou Concord Cancer Center completed the proton equipment installation in September 2020, began clinical trials in November 2022, and obtained the large medical equipment procurement license in September 2024. With this final approval, the center plans to commence proton therapy treatment services soon.
The news was also announced by Concord Healthcare Group, CCM's subsidiary listed on the Hong Kong Stock Exchange (2453.HK) since January 9, 2024.
Concord Medical Services Holdings (NYSE: CCM) announced its 2024 annual general meeting of shareholders, scheduled for December 27, 2024, at 10:00 a.m. (Beijing Time) in Beijing, China. The meeting's primary purpose is to amend the company's memorandum and articles of association to reflect changes in the ratio of American depositary shares (ADSs) to Class A ordinary shares, effective July 30, 2024. Shareholders of record as of November 27, 2024, will be eligible to attend and discuss company affairs with management.
Concord Medical Services Holdings (NYSE: CCM) reported its financial results for the first half of 2024. Total net revenues decreased by 23.1% to RMB218.8 million (US$30.1 million) compared to the same period last year. The company experienced a gross loss of RMB41.6 million (US$5.7 million) and a net loss attributable to ordinary shareholders of RMB172.3 million (US$23.7 million). The hospital business saw a 13.2% decrease in net revenues, while the network business experienced a 35.6% decrease. Despite these challenges, Concord Medical's Guangzhou Hospital obtained a license for proton equipment, which is expected to boost future revenue. The company remains optimistic about its growth potential in the oncology care sector.